Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.

This study has been completed.
Sponsor:
Information provided by:
Prostrakan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00262678
First received: December 6, 2005
Last updated: June 2, 2009
Last verified: June 2009
  Purpose

The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.


Condition Intervention Phase
Pain
Cancer
Drug: EN3267
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.

Resource links provided by NLM:


Further study details as provided by Prostrakan Pharmaceuticals:

Study Start Date: December 2005
Study Completion Date: January 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   17 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females 17 years of age or older
  • Stable cancer-related pain.
  • Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 µg/h, and are on a stable dose of opioid medication for relief of breakthrough pain for at least 14 days prior to screening.
  • Experiencing 1-4 episodes of breakthrough pain per day.
  • Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.

Exclusion Criteria:

  • Are pregnant or lactating.
  • Have uncontrolled or rapidly escalating pain.
  • Have moderate to severe ulcerative mucositis.
  • Have a cardiopulmonary disease that would increase the risk of administering potent opioids.
  • Have neurologic or psychologic disease that would compromise data collection
  • Have any clinically significant condition that would, in the investigator's opinion, preclude study participation.
  • Are currently taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14 days prior to enrolling in the study.
  • Have received strontium 89 therapy within 60 days prior to entering the study.
  • Have received anti-neoplastic therapy within 2 weeks of study entry that, in the investigator's opinion, will influence assessment of breakthrough pain
  • Have received any investigational drug (non-approved) within 30 days prior to the first dose of study medication, or are scheduled to receive an investigational drug other than EN3267 during the course of the study.
  • Have hypersensitivities, allergies, or contraindications to fentanyl.
  • Have a significant prior history of substance abuse or alcohol abuse.
  • May have difficulty complying with the protocol, as assessed by the investigator.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00262678

Locations
United States, North Carolina
Carolinas Pain Institute
Winston-Salem, North Carolina, United States, 27103
Sponsors and Collaborators
Prostrakan Pharmaceuticals
  More Information

No publications provided by Prostrakan Pharmaceuticals

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00262678     History of Changes
Other Study ID Numbers: EN3267-005
Study First Received: December 6, 2005
Last Updated: June 2, 2009
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on April 17, 2014